New ASAP Long-Term Findings Reveal: Disease Risk, Not Remission Status, Drives Transplant Outcomes in Acute Myeloid Leukemia (AML)
In a breakthrough that challenges longstanding therapeutic standards for acute myeloid leukemia (AML), the ASAP trial has presented compelling evidence ...
